Pellagra Treatment Market 2025: Industry Developments, Future Growth, Share & Industry Insights | DSM, Merck KGaA, Foodchem International Corporation, Lasons, Bazayan & Co

Pellagra Treatment Market is estimated to grow at a CAGR of 5% during the forecast period 2024-2031.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/pellagra-treatment-market?sg

USA - Industry Recent Developments 2025:

✅ 30 Apr 2025: Zydus received US FDA approval to market extended-release niacin tablets (500 mg / 750 mg / 1,000 mg) for the U.S. a commercial product launch that directly affects prescription/therapeutic niacin availability.

✅ 2000-2025 (guideline reminder): WHO / US NIH guidance used in clinical practice recommends treating pellagra with nicotinamide / niacin supplementation (WHO commonly cites ~300 mg nicotinamide/day in divided doses for 3-4 weeks in pellagra). This remains the standard of care; recent clinical case reports in 2024-2025 continued to emphasise rapid improvement after niacin therapy in modern cases.

Europe - Industry Recent Developments 2025:

✅ 25 Jan 2025: Jubilant Ingrevia commissioned a cGMP facility for niacinamide (high-bio content) - a capacity / supply move that affects European supply chains for nicotinamide and downstream products (cosmetic/nutraceutical/pharma).

✅ Q2 2025: European nicotinamide prices and supply normalized after volatility; industry reports flagged price softness in several Q2 2025 markets (impacting cost and availability of nicotinamide used for pellagra treatments and topical formulations).

Japan - Industry Recent Developments 2025:

✅ 2025 (published case reports): Clinical literature in 2025 reported modern cases of pellagra and neonatal pellagra, underscoring that isolated cases still occur in developed nations and are treated with niacin/nicotinamide supplementation - these case reports (2025) stress diagnosis and nutritional management rather than new drug launches.

South Korea - Industry Recent Developments 2025:

✅ 2025 (clinical / safety note): Case literature and clinical summaries (including older case series and articles) note drug-induced pellagra (e.g., isoniazid-related) remains a recognized cause in Korea - management is replacement with niacin / nicotinamide and treating underlying cause. A 2025 literature record reiterates vigilance in TB patients on isoniazid.

✅ Jun 2025 (commercial context): Industry pricing and supply reports show niacinamide prices in South Korea reflected demand from cosmetics and nutraceutical sectors (Q2 2025 price points cited in market briefs), which can influence availability/cost of nicotinamide used clinically.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/pellagra-treatment-market?sg

Top market growth drivers:

✅ Demand for niacin / nicotinamide supplements & fortification programs - treatment of pellagra is straightforward (oral nicotinamide/niacin); rising production and broader use of vitamin B3 in supplements and topical/cosmetic formulations expands the addressable market.

✅ Public-health interventions in food-insecure regions - emergency nutrition programs, fortified staples and NGO / government distribution of B-vitamin supplements in Africa, South Asia and parts of Latin America sustain demand for treatment and prevention supplies.

✅ Clinical drivers & drug interactions - secondary pellagra from malabsorption or drug interactions (e.g., isoniazid in TB treatment) creates pockets of clinical need and surveillance-driven treatment programs.

✅ Awareness, diagnostics & targeted screening - improved diagnostic awareness among clinicians and refugee / displaced-person health services increases identification and treatment rates in at-risk populations.

Regional share:

➠ North America - largest commercial share (estimate ~35-45%): multiple market reports identify North America as the leading revenue region (advanced healthcare channels, supplement retail, fortification policy and clinical interventions).

➠ Europe - significant share (estimate ~20-30%): well-developed nutraceutical & pharma channels and regulatory frameworks for fortification and supplementation support demand.

➠ Asia-Pacific (incl. South Asia) - prevention & public-health demand (estimate ~15-25%): higher clinical prevalence pockets and large public-health programs drive volumes, though per-unit pricing is lower.

➠ Latin America / Middle East & Africa - niche but high-need pockets (estimate combined ~5-15%): sporadic outbreaks in food-insecure or displaced populations mean these regions are more program-driven (governments/NGOs) than commercial.

Segments Covered in the Pellagra Treatment Market:

By Type (Primary Pellagra, Secondary Pellagra)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other)

Regional Analysis for Pellagra Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=pellagra-treatment-market?sg

Major Key Players: DSM, Merck KGaA, Foodchem International Corporation, Jubilant Life Sciences Limited, Western Drugs Ltd., Lasons, Bazayan & Co, Resonance Specialties Limited.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.